Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
Former investment relations director receives 15 months in prison for insider trading
September 16, 2025
News Alert
Second Circuit upholds insider trading conviction in the Southern District of New York
September 10, 2025
News Alert
Arizona resident reaches settlement with SEC to resolve insider trading charges
August 28, 2025
News Alert